A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI

Metastatic Colorectal Cancer Clinical Trial

Official title:

An Open-label Phase II Prospective Clinical Trial to Investigate Safety, Tolerability, Maximum Tolerated Dose and Anti-tumor Effect for SCO-101 in Combination With FOLFIRI as a Safe and Efficient Treatment Modality in Metastatic or Advanced Colorectal Cancer (mCRC) Patients With Acquired FOLFIRI Resistant Cancer Disease.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04247256
• Other study ID #: SCO101-001
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: May 14, 2020
• Est. completion date: June 30, 2022

Study information

• Verified date: December 2021
• Source: Scandion Oncology A/S
• Contact: Peter M Vestlev, MD
• Phone: +45 22779696
• Email: pmv[@]scandiononcology.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the combination of SCO-101 to FOLFIRI for the treatment of metastatic colorectal cancer patients who have developed resistance to FOLFIRI treatment. The study is divided in two parts, where the first part evaluates the safety and toxicity of increasing doses of SCO-101 in combination with FOLFIRI at the same dose as the patient has previously developed resistance to. The second part of the study evaluates the safety and efficacy of the combination of FOLFIRI and SCO-101 at the dose level established in the first part.

Description:

This is a multi-center, open label, dose escalation, Phase 2 study of SCO-101 in combination with FOLFIRI in up to 50 mCRC patients. All patients included have previously had effect from treatment with FOLFIRI, but have now progressed (i.e. treatment failure due to acquired resistance).

FOLFIRI is a key anti-cancer chemotherapeutic combination in the treatment of several solid tumor cancers, e.g. colorectal cancer. Cancer resistance to FOLFIRI exposure is a well known phenomenon and can often be attributed to upregulation of cellular efflux pumps, e.g. ATP-Binding Cassette (ABC)G2 and ABCB1, involved in the efflux of the chemotherapeutic agents from the cancer cells and resulting in treatment failure.

SCO-101 is an inhibitor of ATP-Binding Cassette (ABC) efflux pumps and SRPK1 kinase which is responsible for phosphorylation of splicing factors, a key element involved in tumour growth.

The combination of SCO-101 with FOLFIRI is expected to inhibit the active efflux of chemotherapy molecules from the cancer cell thereby re-sensitizing it to the chemotherapeutic agents.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 35
• Est. completion date: June 30, 2022
• Est. primary completion date: June 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria: Subjects are required to meet all of the following criteria for enrollment into the applicable stage (stage 1, stage 2 or stage 3) of the study:

1. Ability to understand and willingness to provide written informed consent before any trial-related activities.

2. Age 18 years or older.

3. Histologically verified colorectal adenocarcinoma.

4. Non-resectable mCRC in patients A. Stage 1 only: with or without known BRAF, KRAS or repair enzyme mutations. B. Stage 2 and stage 3 only: without known BRAF, KRAS or repair enzyme mutations

5. A. Stage 1 only: Documented progressive disease on FOLFIRI treatment regimen (with or without antiangiogenetic and EGFR inhibitory biological treatment).

B. Stage 2 and stage 3 only: Documented progressive disease with a prior benefit (SD for more than 16 weeks, or CR or PR) on FOLFIRI treatment regimen (with or without antiangiogenetic and EGFR inhibitory biological treatment).

6. Maximum reduction of 33% in prior dose of FOLFIRI.

7. No indication for treatment with an oxaliplatin-containing treatment regimen. The patient may have received oxaliplatin treatment after treatment with FOLFIRI.

8. A. Stage 1 only: Evaluable disease by CT scan or MRI. B. Stage 2 and stage 3 only:

Measurable disease by CT scan or MRI, according to RECIST. 1.1.

9. Performance status of ECOG = 1.

10. Recovered to Grade 1 or less from prior surgery or acute toxicities of prior radiotherapy or treatment with cytotoxic or biologic agents.

11. = 2 weeks must have elapsed since any prior surgery.

12. Adequate conditions as evidenced by the following clinical laboratory values:

• Absolute neutrophils count (ANC) = 1.5 x 109/L

• Haemoglobin = 6.0 mmol/L

• Platelets = 100 x 109 /L

• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5 x ULN*

• Total serum bilirubin = 1.0 ULN**

• Alkaline phosphatase = 2.5 x ULN*

• Creatinine = 1.5 ULN

• eGFR within normal limits.

• Adequate blood clothing function as defined by the International Normalized Ratio (INR) = 1.2;

13. Life expectancy equal to or longer than 3 months.

14. Sexually active males and females of child-producing potential must use highly effective contraception (intrauterine devices, hormonal contraceptives (contraceptive pills, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release)) for the study duration and at least 6 months after the last dose of study drug.

15. Signed informed consent.

• AST is not mandatory. In case of known liver metastases with ALT and AST = 5 x ULN and/or alkaline phosphatase = 5 x ULN: Patients who do not conform to the transaminase and/or alkaline phosphatase inclusion criteria, but who by the PI are considered in good PS and otherwise eligible for inclusion, and where the transaminase and/or alkaline phosphatase levels are considered elevated due to other reasons than deteriorated lever capacity, may be considered for inclusion based on conferred agreement between PI and sponsor.

• Unconjugated bilirubin may be measured as the difference between total bilirubin and conjugated bilirubin.

Exclusion Criteria: Subjects meeting any of the following criteria will be excluded from enrollment:

1. Concurrent chemotherapy, radiotherapy, or other investigational drug except non-disease related conditions (e.g. insulin for diabetes) during study period.

2. Malabsorption syndrome or previous surgeries with resection of the stomach or small intestine, whereby absorption of SCO-101 may be affected. This includes patients with ileostomy.

3. Difficulty in swallowing tablets.

4. Clinical symptoms of CNS metastases requiring steroids.

5. Any active infection requiring parenteral or oral antibiotic treatment.

6. Known HIV positivity.

7. Known active hepatitis B or C.

8. Clinical significant (i.e. active) cardiovascular disease:

• Stroke within = 6 months prior to day 1

• Transient ischemic attach (TIA) within = 6 months prior to day 1

• Myocardial infarction within = 6 months prior to day 1

• Unstable angina

• New York Heart Association (NYHA) Grade II or greater congestive heart failure (CHF)

• Serious cardiac arrhythmia requiring medication

9. Mental status is not fit for clinical study or CNS disease including symptomatic epilepsy.

10. Other medications or conditions that in the Investigator's opinion would contraindicate study participation of safety reasons or interfere with the interpretation of study results. Other severe medical conditions, including serious heart disease, unstable diabetes, uncontrolled hypercalcemia, clinically active infections or previous organ transplants. Participation in another clinical trial with experimental medication within 30 days prior to registration.

11. Known hypersensitivity to irinotecan, 5-FU or capecitabine

12. Pregnant women or women who are breastfeeding.

Related Conditions & MeSH terms

• Colorectal Neoplasms
• Metastatic Colorectal Cancer

Intervention

Drug:
• FOLFIRI Protocol
FOLFIRI standard treatment on day 5 to 7 (both days included) of a 14 day period. repeated bi-weekly
• SCO-101
Investigational Medicinal Product, oral tablet administered on day 1 to 6 (both days included) of a 14 day period. repeated bi-weekly

Locations

Country	Name	City	State
Denmark	Aalborg Universitetshospital - Region Nordjylland	Aalborg
Denmark	Herlev Hospital	Herlev
Denmark	Hillerød Hospital	Hillerød
Denmark	Sjællands Universitetshospital, Roskilde	Roskilde
Denmark	Sygehus Sønderjylland	Sønderborg
Denmark	Vejle Sygehus	Vejle
Germany	Charité	Berlin
Germany	Catholic Hospital Bochum - St. Josef-Hospital	Bochum
Germany	University Hospital Of Ulm	Ulm
Spain	Hospital de la Santa Creu in Sant Pau	Barcelona
Spain	Hospital Universitario Valle de Hebrón	Barcelona
Spain	Hospital Clínico Universitario in Valencia	Valencia

Sponsors (2)

Lead Sponsor	Collaborator
Scandion Oncology A/S	TFS Trial Form Support

Countries where clinical trial is conducted

Denmark,  Germany,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of combination of SCO-101 and FOLFIRI	Safety and tolerability by assessing the number, frequency, and severity of adverse events (AEs) collected from the time of first treatment until four weeks after end of treatment to evaluate safety of SCO-101 in combination with FOLFIRI determined according to CTCAE version 5.0	4 cycles (each cycle is 2 weeks)
Primary	Maximum Tolerated Dose	Maximum tolerated dose (MTD) by evaluation of dose-limiting toxicities (DLTs) of SCO-101 in combination with FOLFIRI evaluated by CTCAE v. 5.0 (part 1 only)	1 cycle (each cycle is 2 weeks)
Primary	Objective Response Rate	Objective response rate (ORR) defined as CR and PR using the RECIST v. 1.1	4 cycles (each cycle is 2 weeks)
Secondary	Progression Free Survival (PFS)	Progression free survival (PFS) defined as time in months from the date of first study treatment to the date of disease progression or death from any cause, whichever comes first.	Start of treatment to first objective sign of progression, assessed up to 100 months
Secondary	Duration of Response	Duration of response (from first response to progression)	From first response to progression, assessed up to 100 months
Secondary	Duration of Response compared to prior Duration of response	Duration of response (DOR) after administration of SCO-101 compared to DOR from patients initial FOLFIRI treatment regimen (without SCO-101).	From first response to progression, assessed up to 100 months
Secondary	Overall Survival	Overall survival (OS) defined as time in months from the date of first study treatment to the date of death;	Up to 2 years
Secondary	Clinical Benefit Rate	Clinical benefit rate (CBR) defined as the number of patients obtaining CR, PR, or SD > 16 weeks according to RECIST v.1.1.	from benefit (CR, PR or SD > 16 weeks) to progression, assessed up to 100 months
Secondary	Pharmacokinetic profile of SCO-101 in combination with FOLFIRI	Pharmacokinetic profile of SCO-101 in blood samples	First week of administration (study part 1 only)
Secondary	ctDNA	Change in ctDNA from baseline (prior first dose of SCO-101) until first CT scan	First 4 cycles of treatment (each cycle is 2 weeks) (study part 2 only)
Secondary	Biomarker UGT1A1	Evaluation of Selected UGT1A1 polymorphism in a pre-treatment blood sample	Baseline (pre-treatment (all study parts))
Secondary	Biomarker IndiTreat(TM)	Efficacy of IndiTreat® to predict clinical response to SCO-101 treatment in combination with FOLFIRI from a tumor biopsy sample.	Baseline (pre-treatment tumor biopsy (study part 2 only))
Secondary	Biomarkers ABCG2, ABCB1, SRPK1	Efficacy of molecular biomarkers ABCB1/ABCG2/SRPK1 determined by immunohistochemistry to predict clinical response to SCO-101 treatment	Baseline (Pre-treatment biopsy (study part 2 only))